FDA
-
-
-
-
-
-
-
InflaRx to Report First Quarter 2026 Results on May 7, 2026
-
-
-
-
-
-
-
InflaRx cuts 30% of workforce to focus on izicopan development
-
-
-
-
-
-
-
InflaRx reports positive Phase 2a results for INF904 in two conditions
-
-
-
-
-
-
-
Cantor Fitzgerald Starts Inflarx NV (IFRX) at Overweight
-
-
-
-
-
-
-
InflaRx (IFRX) Receives Positive CHMP Opinion for GOHIBIC for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
-
-
-
-
-
-
-
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
-
-
-
-
-
-
-
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
-
325,852 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

